Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1129, doi. 10.1002/cpdd.984
- Publication type:
- Article
Works matching IS 2160763X AND DT 2023 AND VI 12 AND IP 12
Results: 14
1
2
Support for Removing Pharmacodynamic and Clinical Efficacy Testing of Biosimilars: A Critical Analysis.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1134, doi. 10.1002/cpdd.1349
- By:
- Publication type:
- Article
3
Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1142, doi. 10.1002/cpdd.1339
- By:
- Publication type:
- Article
4
Population Pharmacokinetic Model of N‐Acetylcysteine During Periods of Recurrent Hypoglycemia in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1234, doi. 10.1002/cpdd.1338
- By:
- Publication type:
- Article
5
Bioequivalence of Reference and Biosimilar Preparations of Premixed Biphasic Insulin Aspart: A Comparative Clamp Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1178, doi. 10.1002/cpdd.1333
- By:
- Publication type:
- Article
6
Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug–Drug Interaction Studies in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1241, doi. 10.1002/cpdd.1332
- By:
- Publication type:
- Article
7
Safety, Pharmacokinetics, and Exposure–Response Modeling of Nedosiran in Participants With Severe Chronic Kidney Disease.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1164, doi. 10.1002/cpdd.1320
- By:
- Publication type:
- Article
8
Comparative Pharmacokinetic Profiles of a Novel Low‐Dose Micronized Formulation of Raloxifene 45 mg (AD‐101) and the Conventional Raloxifene 60 mg in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1204, doi. 10.1002/cpdd.1319
- By:
- Publication type:
- Article
9
Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1211, doi. 10.1002/cpdd.1316
- By:
- Publication type:
- Article
10
Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000‐L Scale in Participants with Pompe Disease: A Phase 3/4 Open‐Label Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1185, doi. 10.1002/cpdd.1314
- By:
- Publication type:
- Article
11
Bioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1194, doi. 10.1002/cpdd.1311
- By:
- Publication type:
- Article
12
Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1156, doi. 10.1002/cpdd.1310
- By:
- Publication type:
- Article
13
Pharmacokinetic and Bioequivalence Evaluation of Two Cefprozil Dispersible Tablets in Healthy Chinese Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1229, doi. 10.1002/cpdd.1304
- By:
- Publication type:
- Article
14
Comparative Bioavailability of Two Daily Subcutaneous Doses Versus a Single Dose of Intramuscular and Vaginal Progesterone Formulations in Healthy Postmenopausal Females.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1221, doi. 10.1002/cpdd.1300
- By:
- Publication type:
- Article